Literature DB >> 9828480

Clinical criteria and treatment of segmental versus upper extremity reflex sympathetic dystrophy.

P N Soucacos1, L A Diznitsas, A E Beris, K N Malizos, T A Xenakis, G S Papadopoulos.   

Abstract

The effectiveness of a multimodal treatment protocol in the long-term management of upper extremity reflex sympathetic dystrophy (RSD), as well as of isolated finger involvement, was analyzed. In the present series, 62 patients diagnosed with RSD were treated and followed for a mean of 22.2 +/- 1.5 months. The findings in the present study indicate that: 1) RSD occurs predominantly in females (female:male, 3:1); 2) regional dystrophy is twice as common as segmental dystrophy; 3) segmental dystrophy is most often associated with minor traumatic dystrophy, whereas regional dystrophy is more evenly distributed among the various clinical types; 4) patients with regional dystrophy score their pain significantly higher; and 5) segmental and regional dystrophy respond with equal satisfaction to the multimodal treatment regimen. In conclusion, the weight of the available evidence strongly suggests that RSD is a complex multifaceted disease entity which responds well when managed with a multimodal treatment program aimed at the various interacting components of the disorder. Furthermore, the finding that segmental dystrophy did not behave differently from the treatment protocol compared to extensive upper extremity RSD, suggests that the anatomic location of the syndrome may not significantly alter the course of the disease during treatment.

Entities:  

Mesh:

Year:  1998        PMID: 9828480

Source DB:  PubMed          Journal:  Acta Orthop Belg        ISSN: 0001-6462            Impact factor:   0.500


  2 in total

Review 1.  Controversies surrounding reflex sympathetic dystrophy: a review article.

Authors:  R P Pawl
Journal:  Curr Rev Pain       Date:  2000

Review 2.  Diagnosis of partial complex regional pain syndrome type 1 of the hand: retrospective study of 16 cases and literature review.

Authors:  Michel Konzelmann; Olivier Deriaz; François Luthi
Journal:  BMC Neurol       Date:  2013-03-18       Impact factor: 2.474

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.